Clinical Trial Update: A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis [Phase 3]

View source ↗

Summary

Phase 3 trial of daily oral laquinimod 0.6 mg in relapsing multiple sclerosis terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• Laquinimod (laquinimod)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Relapsing Multiple Sclerosis | Phase 3 | Status: TERMINATED | Results posted: 2019-01-09